[Trastuzumab Deruxtecan for EGFR-mutant Lung Adenocarcinoma with Acquired High-level HER2 Amplification: A Case Report]. [PDF]
Zhongguo Fei Ai Za ZhiGe X, Chen H, Cui S.
europepmc +1 more source
Alternate-day Capecitabine Plus Trastuzumab for Frail HER2-positive Gastric Cancer: A Pilot Case Series. [PDF]
In VivoOdaira N, Sasaki M, Kanda J, Muneoka K.
europepmc +1 more source
Diagnostic and Therapeutic Challenges Related to HER2 Heterogeneity in Gastric Cancer: Bridging Molecular Pathology and Clinical Decision-Making. [PDF]
Int J Mol SciRosanu NM +6 more
europepmc +1 more source
Invasive ductal and lobular carcinoma and receptor status in the genetic context of breast cancer. [PDF]
Sci RepAl-Masri M, Alayyan O, Safi Y.
europepmc +1 more source
Hsp90: A means to an end. [PDF]
Cell Stress ChaperonesWhalen KM, Freeman BC.
europepmc +1 more source
Trojan horses at leptomeningeal cellular gates: Antibody-drug conjugates deliver cytotoxic payloads. [PDF]
MedNikanjam M, Kurzrock R.
europepmc +1 more source
Dynamic Binder Exchange Improves Protein Labeling Efficiency in DNA-PAINT up to 15-Fold. [PDF]
Angew Chem Int Ed EnglSteinek C +5 more
europepmc +1 more source
FGFR2-Rearranged Biliary Tract Cancer: Biology, Resistance Mechanisms, and Emerging Therapeutic Strategies. [PDF]
Cancers (Basel)Xin X, Miao R.
europepmc +1 more source
Exploring the mechanisms of luteolin in treating polycystic ovary syndrome and endometriosis via network pharmacology, molecular docking, and molecular dynamics simulation. [PDF]
Medicine (Baltimore)Chen R +6 more
europepmc +1 more source
HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC). [PDF]
Int J Mol SciRichani Meinhardt FW +5 more
europepmc +1 more source